Clinical Trial Update: Study of Orelabrutinib in Combination With Gemox in Refractory / Relapsed Diffuse Large B-cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating orelabrutinib in combination with Gemox for refractory/relapsed diffuse large B-cell lymphoma is underway, with the status n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Orelabrutinib (orelabrutinib)

Snippet

Sponsor: Sun Yat-sen University | Conditions: DLBCL | Phase 2 | Status: UNKNOWN